Decellularized matrices
Stripping the cells from real tissue and keeping the scaffold nature already built.
Rather than fabricating a scaffold, decellularization takes existing tissue and removes its cells with detergents, enzymes, or physical methods, leaving the extracellular matrix intact. The result retains an architecture no manufacturing process can currently match — including, in whole organs, the vascular tree itself, which is a direct answer to the diffusion limit.
The retained matrix also keeps much of its biological signalling: bound growth factors, native adhesion sites, tissue-appropriate mechanics. Decellularized products are established clinically in several soft-tissue applications, and processed allograft bone is arguably the same idea applied to the skeleton.
The tension is inherent. Decellularize gently and residual cellular material risks an immune reaction; decellularize aggressively and the matrix that made it worthwhile is damaged. Recellularizing the construct afterward — getting cells to repopulate it evenly — remains largely unsolved.
Related articles
- FoundationsThe extracellular matrixThe structural and signaling scaffold cells build around themselves — and the template engineered scaffolds try to imitate.
- BiomaterialsScaffold design principlesPorosity, strength, and degradation rate — the competing requirements every scaffold has to reconcile.
- FoundationsVascularization: the diffusion limitWhy engineered tissue thicker than a couple of hundred microns fails without a blood supply — the field's most stubborn bottleneck.
- BoneBone grafting: autograft, allograft, and substitutesThe established clinical standard for replacing missing bone, and the trade-offs that motivate engineered alternatives.
- Biomaterials3D-printed bone scaffoldsAdditive manufacturing lets scaffold architecture be specified directly — and patient-specific.
- BiomaterialsChitosan in tissue engineeringA polysaccharide derived from crustacean shells, structurally reminiscent of the body's own glycosaminoglycans.